Efficacy News and Research

RSS

The maternal RSV vaccine from Pfizer protects newborns against severe illness

Pfizer announced its maternal vaccine against RSV to be almost 82% effective in protecting infants for the first 90 days of life against severe illness.

1 Nov 2022

Progress and challenges in the development of mRNA vaccines against respiratory syncytial virus

New research discussed the structure and life cycle of respiratory syncytial virus (RSV), the current research on the treatment and prevention of RSV infections, and the advancements in RSV mRNA vaccine technology after the surge in vaccine research during the COVID-19 pandemic.

1 Nov 2022

Cohort study determines how often COVID-19 symptoms recurred

Researchers at University of California San Diego School of Medicine, with colleagues from the ACTIV-2 trial, part of the U.S. government's response to COVID-19, investigated whether symptoms of COVID-19 recurred following a two-day symptom-free period in persons who did not receive any treatment for the disease.

1 Nov 2022

New nanovaccine greatly improves cytokine production

Cancer immunotherapies, such as immune checkpoint inhibition therapy, have been attracting attention in recent years as new methods for treating cancer. However, immune checkpoint inhibition therapy is only effective in 20%–30% of cancer patients, so developing better drug delivery systems to induce anticancer cellular immunity is necessary.

1 Nov 2022

Social protection program shows promise in helping poor households deal with natural disasters

An interventional social protection program called Program Keluarga Harapan (PKH) shows positive results in helping poor households develop proactive coping strategies before and during natural disasters, leading to social and economic resilience.

31 Oct 2022

Monoclonal antibody shows efficacy in preventing malaria infection in African adults

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found.

31 Oct 2022

New research suggests booster dose of Novavax NVX-CoV2373 vaccine is effective against SARS-CoV-2 Omicron subvariants

A new study evaluated the neutralizing antibody titers against the SARS-CoV-2 Omicron variant and its sub-lineages after two and three doses of the Novavax protein nanoparticle vaccine NVX-CoV2373.

31 Oct 2022

Italian study evaluates COVID-19 reinfection risk among previously infected and vaccinated individuals

Researchers from Italy investigated the risk of SARS-CoV-2 reinfection and hospitalization among individuals with vaccinations and previous SARS-CoV-2 infections.

31 Oct 2022

SpyCatcher-SpyTag technology used to develop recombinant protein-based intranasal vaccine against SARS-CoV-2

The findings of a new study showed that the intranasal SpyCage vaccine platform can be protective against SARS-CoV-2 and may prove to be a versatile and adaptable modality for the formulation of intranasal vaccines that target respiratory pathogens.

31 Oct 2022

An innovative nasal vaccine strategy to combat COVID

In a recent study published in the journal Science, researchers at Yale University developed a novel coronavirus disease 2019 (COVID-19) vaccination strategy termed 'prime and spike' (P&S) that leveraged existing systemic immunity triggered by parenteral vaccination (prime) to boost immunity at the respiratory mucosa.

31 Oct 2022

Psychosocial impact on pandemic workers in Shanghai during Omicron wave lockdown

In a recent study posted to the medRxiv* server, researchers assessed the well-being of all workers involved in coronavirus disease 2019 (COVID-19) testing between April and June 2022, i.e., during the Omicron wave lockdown in Shanghai, China.

30 Oct 2022

Estimating the risk of airborne SARS-CoV-2 transmission in a train carriage

Researchers evaluate the risk of airborne transmission of SARS-CoV-2 in a mechanically ventilated inter-city train carriage.

30 Oct 2022

Piceatannol and mTOR inhibitor combination proves be an attractive therapeutic strategy for gastric cancer

This study is led by Dr. Longtao Huangfu, and Dr. Xiaoyang Wang (Peking University Cancer Hospital & Institute). A diet of fresh fruits and vegetables may reduce the prevalence of cancers, including GC (Eusebi et al., 2020; Liu et al., 2021).

28 Oct 2022

New EULAR task force aims to help achieve gender equity in academic rheumatology

Evidence on gender equity in academic rheumatology in Europe is currently limited. This knowledge gap has a direct effect on the ability of professional bodies to improve gender equity.

28 Oct 2022

Updated EULAR recommendations for children with pedAIIRD

People with autoimmune or auto-inflammatory rheumatic diseases have an increased risk of infections. This can be due to the underlying disease itself, or may be caused by treatment with immunomodulating or immunosuppressive drugs.

28 Oct 2022

Startup receives federal grant for developing technology to detect and treat stress, anxiety

A high-tech startup that uses game-based interventions to help users identify stress- and anxiety-related events in real time and receive a personalized intervention has been awarded a federal grant to partially develop its technology through research at Purdue University's College of Engineering.

28 Oct 2022

First anti-SARS Cov2 monoclonal antibody candidate of SpikImm demonstrates excellent tolerance

SPK001, the first anti-SARS Cov2 monoclonal antibody candidate of SpikImm, a French biotechnology company founded by Truffle Capital, originally discovered by the Institut Pasteur's Human Immunology Laboratory, directed by Dr. Hugo Mouquet (Inserm Joint Research Unit), has been tested on three initial cohorts of healthy volunteers, and has demonstrated excellent tolerance, in the context of the Phase 1 clinical study, recently labeled as a "national priority" by CAPNET (National Steering Committee for Therapeutic Trials and other Research on Covid-19).

28 Oct 2022

Novel nanotechnology triggers potent therapeutic anti-tumor immune responses against multiple cancers

A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers.

28 Oct 2022

E-cigarette use alters respiration but does not impair lung function, according to new findings

A new study indicated that although vaping increases airway resistance, it does not impact lung function.

28 Oct 2022

Scientists computationally restore the potency of an antibody against SARS-CoV-2 Omicron subvariants

A team of researchers from the United States computationally modified the COV2-2130 monoclonal antibody to restore its neutralizing ability against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants, while retaining efficacy against the Delta and wild-type strains.

27 Oct 2022

Efficacy News and Research

The maternal RSV vaccine from Pfizer protects newborns against severe illness

Progress and challenges in the development of mRNA vaccines against respiratory syncytial virus

Cohort study determines how often COVID-19 symptoms recurred

New nanovaccine greatly improves cytokine production

Social protection program shows promise in helping poor households deal with natural disasters

Monoclonal antibody shows efficacy in preventing malaria infection in African adults

New research suggests booster dose of Novavax NVX-CoV2373 vaccine is effective against SARS-CoV-2 Omicron subvariants

Italian study evaluates COVID-19 reinfection risk among previously infected and vaccinated individuals

SpyCatcher-SpyTag technology used to develop recombinant protein-based intranasal vaccine against SARS-CoV-2

An innovative nasal vaccine strategy to combat COVID

Psychosocial impact on pandemic workers in Shanghai during Omicron wave lockdown

Estimating the risk of airborne SARS-CoV-2 transmission in a train carriage

Piceatannol and mTOR inhibitor combination proves be an attractive therapeutic strategy for gastric cancer

New EULAR task force aims to help achieve gender equity in academic rheumatology

Updated EULAR recommendations for children with pedAIIRD

Startup receives federal grant for developing technology to detect and treat stress, anxiety

First anti-SARS Cov2 monoclonal antibody candidate of SpikImm demonstrates excellent tolerance

Novel nanotechnology triggers potent therapeutic anti-tumor immune responses against multiple cancers

E-cigarette use alters respiration but does not impair lung function, according to new findings

Scientists computationally restore the potency of an antibody against SARS-CoV-2 Omicron subvariants

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News